Nkarta, Inc.

Stage 4 · Declining · week 1

As of Oct 22, 2026, Nkarta is in Stage 4, the downtrend phase, now in its first week (since Oct 21, 2026). It closed at $1.74, 52.6% below its 52-week high and below its 200-day average, which is rising.

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. More about the company

$1.74

-0.57% today

$125M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is NKTX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 16w

S4 46w

S2 23w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 11w → S1 8w → S2 16w → S3 11w → S4 46w → S1 6w → S4 3w → S1 6w → S2 9w → S3 7w → S4 4w → S1 2w → S2 23w → S3 12w → S2 1w → S3 1w → S4 1w current

Total tracked: 166 weeks across 17 stage runs.

NKTX among Biotechnology269th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…269	NKTXNkarta, Inc.	Stage 4 · wk 1	35	−37.0%

vs 52W High

-52.6%

$1.73 lo$3.67 hi

52.6% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 1

1w13w26w

Week 1, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-31.7%

200 DMA: $2.55 · rising

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

2.52x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-37.0%

-23.3%

-41.6%

YTD

-7.0%

-27.2%

Scan Membership

Breakout Watch

Latest: 2024-01-04

2 appearances in last 60 days. First seen: 2022-08-12.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 1 · Vol 2.52x

2026-10-21S43→4

Wk 1 · Vol 1.51x

2026-10-20S32→3

Wk 1 · Vol 1.77x

2026-10-19S2

Wk 1 · Vol 2.28x

2026-10-16S2

Wk 1 · Vol 2.89x

2026-10-15S23→2

Wk 1 · Vol 2.48x

2026-10-14S3

Wk 12 · Vol 1.18x

2026-10-13S3

Wk 12 · Vol 1.34x

2026-10-12S3

Wk 12 · Vol 1.01x

2026-10-09S3

Wk 12 · Vol 1.53x

2026-10-08S3

Wk 12 · Vol 1.22x

2026-10-07S3

Wk 11 · Vol 0.96x

Moving averages & range

50 DMA

$2.53

200 DMA

$2.55

52W High

$3.67

52W Low

$1.73

5D Low

$1.74

Resistance levels (recent highs)

20d High

$2.75

60d High

$3.23

120d High

$3.67

250d High

$3.67

Next resistance

+58.0%

to 20d High

ROE

-38.8%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.5

Nkarta: quick answers

What stage is Nkarta in?

As of Oct 22, 2026, Nkarta (NKTX) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 21, 2026 and is in its first week there. What the four stages mean

Is Nkarta in an uptrend?

No. Nkarta is in a Stage 4 downtrend. It trades 31.7% below its 200-day average, which is rising.

How far is Nkarta from its 52-week high?

Nkarta closed at $1.74 on Oct 22, 2026, 52.6% below its 52-week high of $3.67. Its 52-week low is $1.73.

How has Nkarta performed over the past year?

As of Oct 22, 2026, Nkarta is down 27.2% over the past year and down 7.0% so far in 2026.

Which sector and industry is Nkarta in?

Nkarta is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.